Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Arcutis Biotherapeutics (ARQT) EBITDA Margin (2022 - 2025)

Arcutis Biotherapeutics (ARQT) has 4 years of EBITDA Margin data on record, last reported at 13.24% in Q4 2025.

  • For Q4 2025, EBITDA Margin rose 2957.0% year-over-year to 13.24%; the TTM value through Dec 2025 reached 4.3%, up 7979.0%, while the annual FY2025 figure was 4.3%, 7979.0% up from the prior year.
  • EBITDA Margin reached 13.24% in Q4 2025 per ARQT's latest filing, up from 7.44% in the prior quarter.
  • Across five years, EBITDA Margin topped out at 13.24% in Q4 2025 and bottomed at 14903.86% in Q3 2022.
  • Average EBITDA Margin over 4 years is 1627.03%, with a median of 156.77% recorded in 2023.
  • Peak YoY movement for EBITDA Margin: soared 1475501bps in 2023, then soared 2957bps in 2025.
  • A 4-year view of EBITDA Margin shows it stood at 2415.03% in 2022, then surged by 80bps to 488.66% in 2023, then surged by 97bps to 16.33% in 2024, then surged by 181bps to 13.24% in 2025.
  • Per Business Quant database, its latest 3 readings for EBITDA Margin were 13.24% in Q4 2025, 7.44% in Q3 2025, and 19.36% in Q2 2025.